葛根素注射液联合依帕司他治疗糖尿病周围神经病变的临床疗效  

Clinical efficacy of Puerarin injection combined with epalrestat in the treatment of diabetic peripheral neuropathy

作　　者：曹昌斧 李富元 CAO Chang-fu;LI Fu-yuan(Linyi Central Hospital,Linyi 276400,China)

机构地区：[1]山东省临沂市中心医院,276400

出　　处：《中国实用医药》2023年第1期32-35,共4页China Practical Medicine

摘　　要：目的 探讨葛根素注射液联合依帕司他治疗糖尿病周围神经病变(DPN)的临床效果。方法 86例DPN患者,根据随机数字表法分为对照组和观察组,各43例。两组患者均给予控制血糖、饮食疗法及运动指导等常规治疗,在此基础上,对照组患者给予依帕司他治疗,观察组患者给予葛根素注射液联合依帕司他治疗。比较两组患者的临床疗效、药物不良反应发生情况,治疗前后腓神经的运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)及神经病变主觉症状问卷(TSS)评分。结果 观察组的临床治疗总有效率为93.02%,高于对照组的72.09%,差异有统计学意义(P<0.05)。治疗后,两组患者腓总神经的MNCV及腓浅神经、腓肠神经的SNCV均快于本组治疗前,且观察组患者腓总神经的MNCV及腓浅神经、腓肠神经的SNCV分别为(44.65±4.21)、(44.83±4.26)、(45.87±4.32)m/s,快于对照组的(40.82±3.24)、(41.65±3.86)、(42.65±4.12)m/s,差异有统计学意义(P<0.05)。治疗后,两组患者TSS评分均低于本组治疗前,且观察组患者TSS评分(5.12±1.96)分低于对照组的(7.64±2.13)分,差异具有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(χ^(2)=0.156, P>0.05)。结论 葛根素注射液联合依帕司他治疗DPN临床疗效显著,能够改善患者临床症状,提高周围神经传导速度,且安全性高,值得临床推广。Objective To discuss the clinical effect of Puerarin injection combined with epalrestat in the treatment of diabetic peripheral neuropathy(DPN). Methods A total of 86 patients with DPN were divided into control group and observation group according to the random numerical table, with 43 cases in each group. Patients in both groups were given conventional treatments including blood glucose control, diet therapy and exercise instruction. On this basis, patients in the control group were treated with epalrestat, and patients in the observation group were treated with Puerarin injection combined with epalrestat. Both groups were compared in terms of clinical efficacy, occurrence of adverse drug reactions, motor nerve conduction velocity(MNCV), sensory nerve conduction velocity(SNCV) and total symptom score(TSS) before and after treatment. Results The total effective rate of clinical treatment in the observation group was 93.02%, which was higher than 72.09% in the control group,and the difference was statistically significant(P<0.05). After treatment, the MNCV of the common peroneal nerve and the SNCV of the superficial peroneal nerve and the sural nerve in the two groups were faster than those before treatment in this group;the MNCV of the common peroneal nerve, the SNCV of the superficial peroneal nerve and the SNCV of the sural nerve in the observation group were(44.65±4.21),(44.83±4.26) and(45.87±4.32) m/s,which were faster than(40.82±3.24),(41.65±3.86) and(42.65±4.12) m/s in the control group;the differences were statistically significant(P<0.05). After treatment, the TSS score in both groups was lower than that before treatment in this group, and the TSS score(5.12±1.96) points in the observation group was lower than(7.64±2.13) points in the control group;the differences were statistically significant(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(χ^(2)=0.156, P>0.05).Conclusion Puerarin injection combined with epalrestat has sign

关 键 词：糖尿病周围神经病变 葛根素注射液 依帕司他 

分 类 号：R587.2[医药卫生—内分泌]